Novo Nordisk said Thursday that the rampant growth of the U.S.' compounded drug industry was hurting Wegovy sales, and warned ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the ...

The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...